albuterol (Armstrong Albuterol HFA) vs Salmeterol (DISKUS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Armstrong Albuterol HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: April 2028 · NCT07426458 (registry estimate)
No aligned efficacy figure on record for this race.
Salmeterol (DISKUS)
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Armstrong Albuterol HFA) | Salmeterol (DISKUS) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00667407 | —Trial running · NCT05776927 |
| Trough FEV1, change | —Not posted · NCT00667407 | —Trial running · NCT05776927 |
| ACQ-5, change | —Not posted · NCT00667407 | —Trial running · NCT05776927 |
| OCS dose reduction | —Not posted · NCT00667407 | —Trial running · NCT05776927 |
Severe exacerbations, annualised rate
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Salmeterol (DISKUS)
- —Trial running · NCT05776927
Trough FEV1, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Salmeterol (DISKUS)
- —Trial running · NCT05776927
ACQ-5, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Salmeterol (DISKUS)
- —Trial running · NCT05776927
OCS dose reduction
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Salmeterol (DISKUS)
- —Trial running · NCT05776927
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.
Salmeterol (DISKUS): registry results are on file for Asthma, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · Salmeterol (DISKUS)'s landscape